Biocytogen Pharmaceuticals (Beijing) Co., Ltd. released its revised Articles of Association (effective May 2026), setting out comprehensive rules for capital structure, corporate governance, profit distribution and internal controls.
Key Capital Information • Registered capital is fixed at 446.90 million ordinary shares (par value RMB1.00 each). • The company operates a dual-listing structure: RMB-denominated A shares are deposited with China Securities Depository & Clearing Corp., while H shares are held through a Hong Kong registrar. • Share buy-backs are limited to specific circumstances (e.g., employee incentives, bond conversion) and total treasury shares must not exceed 10% of issued capital.
Governance Structure • Shareholders’ General Meeting retains exclusive authority over major matters such as amendments to the articles, capital changes, mergers, major asset transactions and the appointment of auditors. • The Board of Directors comprises nine members, including three independent non-executive directors and one employee representative. A cumulative voting system applies when a single shareholder (or concert party) holds 30% or more of voting rights. • The Audit Committee (three directors, at least two of whom are independent) replaces a traditional Supervisory Board and holds statutory supervisory powers, including approval of financial disclosures, auditor engagement and oversight of internal controls. • Other special board committees—Strategy, Nomination, and Remuneration & Assessment—must each have independent directors as conveners and a majority of independents for the latter two.
Profit Distribution Framework • Biocytogen adopts a residual-dividend model, prioritising cash payouts. When the parent-company financials show positive undistributed profits, annual cash dividends (including interim payments) must account for no less than 10% of net profit attributable to equity holders. • Cash dividends are mandatory at least once a year; payment must be completed within two months of shareholder approval. • Stock dividends or reserve-to-capital conversions are permitted only after cash dividend thresholds are met and must be backed by audited interim or quarterly financials. • Future modifications to the dividend policy require two-thirds approval of voting shareholders, independent director endorsement and disclosure.
Transaction and Guarantee Thresholds • Shareholder approval is required for guarantees or asset transactions exceeding 30% of the company’s latest audited total assets, or for related-party deals above RMB30 million that represent at least 1% of assets or market capitalisation. • Board approval covers mid-sized transactions where key financial metrics surpass 10% of assets, revenue or profit but remain below shareholder thresholds. • Guarantees to related parties need approval by two-thirds of non-related directors and subsequent shareholder consent, with conflicted parties abstaining.
Internal Control & Audit • A dedicated internal audit department, overseen by the Audit Committee, monitors business activities, risk management and financial reporting. • Any discovery of material issues must be reported directly to the Audit Committee, and annual internal control evaluation reports are mandatory.
Merger, Division & Capital Adjustments • Mergers not exceeding 10% of net assets can proceed with board approval; larger restructurings require shareholder resolutions. • Capital reductions trigger creditor notification within 10 days and public announcement within 30 days; remaining assets are allocated to shareholders only after debt settlement.
Senior Management • The company employs a General Manager, several Deputy General Managers, a Chief Financial Officer and a Board Secretary, all appointed by the Board. • Senior officers must not hold administrative posts in entities controlled by the company’s controlling shareholder or actual controller and may receive remuneration solely from Biocytogen.
These revised Articles codify Biocytogen’s post-dual listing governance standards, aligning corporate practice with PRC Company Law, CSRC regulations and Hong Kong Stock Exchange requirements.
Comments